Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: EDEM2

Gene summary for EDEM2

Gene summary.

Gene information	Species	Human
	Gene symbol	EDEM2
	Gene ID	55741
	Gene name	ER degradation enhancing alpha-mannosidase like protein 2
	Gene Alias	C20orf31
	Cytomap	20q11.22
	Gene Type	protein-coding
	GO ID	GO:0005975
	UniProtAcc	Q9BV94

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
55741	EDEM2	LZE4T	Human	Esophagus	ESCC	1.51e-11	2.63e-01	0.0811
55741	EDEM2	LZE5T	Human	Esophagus	ESCC	4.63e-02	1.68e-01	0.0514
55741	EDEM2	LZE22T	Human	Esophagus	ESCC	2.61e-05	3.34e-01	0.068
55741	EDEM2	LZE24T	Human	Esophagus	ESCC	1.28e-28	7.83e-01	0.0596
55741	EDEM2	LZE21T	Human	Esophagus	ESCC	1.10e-02	2.89e-01	0.0655
55741	EDEM2	LZE6T	Human	Esophagus	ESCC	3.57e-07	3.14e-01	0.0845
55741	EDEM2	P1T-E	Human	Esophagus	ESCC	3.51e-04	2.76e-01	0.0875
55741	EDEM2	P2T-E	Human	Esophagus	ESCC	5.95e-21	3.58e-01	0.1177
55741	EDEM2	P4T-E	Human	Esophagus	ESCC	5.39e-13	2.97e-01	0.1323
55741	EDEM2	P5T-E	Human	Esophagus	ESCC	1.85e-07	1.39e-01	0.1327
55741	EDEM2	P8T-E	Human	Esophagus	ESCC	7.39e-24	3.88e-01	0.0889
55741	EDEM2	P9T-E	Human	Esophagus	ESCC	2.28e-14	3.30e-01	0.1131
55741	EDEM2	P10T-E	Human	Esophagus	ESCC	3.55e-17	3.27e-01	0.116
55741	EDEM2	P11T-E	Human	Esophagus	ESCC	1.13e-11	4.84e-01	0.1426
55741	EDEM2	P12T-E	Human	Esophagus	ESCC	1.78e-21	4.55e-01	0.1122
55741	EDEM2	P15T-E	Human	Esophagus	ESCC	2.06e-26	5.66e-01	0.1149
55741	EDEM2	P16T-E	Human	Esophagus	ESCC	5.84e-35	6.43e-01	0.1153
55741	EDEM2	P17T-E	Human	Esophagus	ESCC	1.49e-09	3.74e-01	0.1278
55741	EDEM2	P19T-E	Human	Esophagus	ESCC	2.15e-05	3.21e-01	0.1662
55741	EDEM2	P20T-E	Human	Esophagus	ESCC	6.76e-33	7.02e-01	0.1124

Page: 1 2 3 4 5 6

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:001603234	Thyroid	ATC	viral process	241/6293	415/18723	5.50e-25	2.04e-22	241
GO:003238632	Thyroid	ATC	regulation of intracellular transport	203/6293	337/18723	6.16e-24	1.85e-21	203
GO:003315726	Thyroid	ATC	regulation of intracellular protein transport	147/6293	229/18723	2.01e-21	4.38e-19	147
GO:003238825	Thyroid	ATC	positive regulation of intracellular transport	131/6293	202/18723	8.20e-20	1.24e-17	131
GO:009031624	Thyroid	ATC	positive regulation of intracellular protein transport	107/6293	160/18723	6.82e-18	7.84e-16	107
GO:190495128	Thyroid	ATC	positive regulation of establishment of protein localization	177/6293	319/18723	5.43e-16	4.29e-14	177
GO:003596633	Thyroid	ATC	response to topologically incorrect protein	102/6293	159/18723	2.87e-15	1.99e-13	102
GO:005122234	Thyroid	ATC	positive regulation of protein transport	165/6293	303/18723	4.94e-14	2.69e-12	165
GO:000698633	Thyroid	ATC	response to unfolded protein	88/6293	137/18723	2.04e-13	9.91e-12	88
GO:003650322	Thyroid	ATC	ERAD pathway	72/6293	107/18723	1.05e-12	4.41e-11	72
GO:003043322	Thyroid	ATC	ubiquitin-dependent ERAD pathway	60/6293	85/18723	3.38e-12	1.38e-10	60
GO:001908023	Thyroid	ATC	viral gene expression	64/6293	94/18723	8.44e-12	3.16e-10	64
GO:003097015	Thyroid	ATC	retrograde protein transport, ER to cytosol	23/6293	29/18723	5.84e-07	8.19e-06	23
GO:190351315	Thyroid	ATC	endoplasmic reticulum to cytosol transport	23/6293	29/18723	5.84e-07	8.19e-06	23
GO:003252715	Thyroid	ATC	protein exit from endoplasmic reticulum	32/6293	48/18723	2.88e-06	3.30e-05	32
GO:001908213	Thyroid	ATC	viral protein processing	18/6293	29/18723	1.58e-03	7.98e-03	18
GO:007086113	Thyroid	ATC	regulation of protein exit from endoplasmic reticulum	17/6293	27/18723	1.70e-03	8.47e-03	17
GO:190415212	Thyroid	ATC	regulation of retrograde protein transport, ER to cytosol	10/6293	14/18723	4.31e-03	1.80e-02	10
GO:000910011	Thyroid	ATC	glycoprotein metabolic process	153/6293	387/18723	7.90e-03	3.06e-02	153
GO:19011363	Thyroid	ATC	carbohydrate derivative catabolic process	73/6293	172/18723	9.43e-03	3.47e-02	73

Page: 1 2 3 4 5 6 7 8

Enriched KEGG pathways.

Pathway ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	qvalue	Count
hsa04141211	Esophagus	ESCC	Protein processing in endoplasmic reticulum	147/4205	174/8465	3.29e-22	1.10e-19	5.64e-20	147
hsa04141310	Esophagus	ESCC	Protein processing in endoplasmic reticulum	147/4205	174/8465	3.29e-22	1.10e-19	5.64e-20	147
hsa0414122	Liver	HCC	Protein processing in endoplasmic reticulum	146/4020	174/8465	7.34e-24	2.46e-21	1.37e-21	146
hsa0414132	Liver	HCC	Protein processing in endoplasmic reticulum	146/4020	174/8465	7.34e-24	2.46e-21	1.37e-21	146
hsa0414130	Oral cavity	OSCC	Protein processing in endoplasmic reticulum	143/3704	174/8465	6.82e-26	2.28e-23	1.16e-23	143
hsa04141113	Oral cavity	OSCC	Protein processing in endoplasmic reticulum	143/3704	174/8465	6.82e-26	2.28e-23	1.16e-23	143
hsa04141210	Oral cavity	LP	Protein processing in endoplasmic reticulum	113/2418	174/8465	8.74e-24	5.82e-22	3.76e-22	113
hsa0414138	Oral cavity	LP	Protein processing in endoplasmic reticulum	113/2418	174/8465	8.74e-24	5.82e-22	3.76e-22	113
hsa0414145	Oral cavity	EOLP	Protein processing in endoplasmic reticulum	70/1218	174/8465	2.84e-17	3.06e-15	1.81e-15	70
hsa0414155	Oral cavity	EOLP	Protein processing in endoplasmic reticulum	70/1218	174/8465	2.84e-17	3.06e-15	1.81e-15	70

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

EDEM2

SNV

Missense_Mutation

c.1079C>A

p.Thr360Lys

p.T360K

Q9BV94

protein_coding

deleterious(0.03)

possibly_damaging(0.725)

TCGA-A8-A075-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

epirubicin

EDEM2

SNV

Missense_Mutation

rs140405715

c.1132N>G

p.Met378Val

p.M378V

Q9BV94

protein_coding

deleterious(0.04)

possibly_damaging(0.718)

TCGA-A8-A08S-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

anastrozole

EDEM2

SNV

Missense_Mutation

novel

c.772N>A

p.Asp258Asn

p.D258N

Q9BV94

protein_coding

deleterious(0)

probably_damaging(1)

TCGA-AC-A62V-01

Breast

breast invasive carcinoma

Male

<65

III/IV

Targeted Molecular therapy

denosumab

EDEM2

SNV

Missense_Mutation

rs754555510

c.476N>A

p.Arg159Gln

p.R159Q

Q9BV94

protein_coding

tolerated(0.29)

benign(0.145)

TCGA-AN-A0AK-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

EDEM2

SNV

Missense_Mutation

rs146309337

c.1565N>T

p.Ser522Leu

p.S522L

Q9BV94

protein_coding

tolerated(0.32)

benign(0)

TCGA-B6-A402-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

cyclophosphamide

EDEM2

SNV

Missense_Mutation

c.1706T>C

p.Leu569Ser

p.L569S

Q9BV94

protein_coding

deleterious_low_confidence(0)

benign(0.075)

TCGA-D8-A1XQ-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

EDEM2

SNV

Missense_Mutation

novel

c.1042N>C

p.Gly348Arg

p.G348R

Q9BV94

protein_coding

tolerated(0.06)

probably_damaging(0.964)

TCGA-GI-A2C9-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unspecific

EDEM2

insertion

In_Frame_Ins

novel

c.300_301insTCATTCTTATAC

p.Val100_Leu101insSerPheLeuTyr

p.V100_L101insSFLY

Q9BV94

protein_coding

TCGA-B6-A0IA-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

EDEM2

insertion

Nonsense_Mutation

novel

c.299_300insTTGTCATCTGTAAATGAAG

p.Leu101CysfsTer4

p.L101Cfs*4

Q9BV94

protein_coding

TCGA-B6-A0IA-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

EDEM2

insertion

Frame_Shift_Ins

novel

c.761_762insAGTGCCTGCAGAATCAGTTCTGAATTCAGAGTCACTAT

p.Ala255ValfsTer24

p.A255Vfs*24

Q9BV94

protein_coding

TCGA-BH-A0DP-01

Breast

breast invasive carcinoma

Female

<65

I/II

Hormone Therapy

arimidex

Page: 1 2 3 4 5 6

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1